Company registration number 10242963 (England and Wales)
NOVUS MED LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025
PAGES FOR FILING WITH REGISTRAR
NOVUS MED LTD
CONTENTS
Page
Statement of financial position
1 - 2
Notes to the financial statements
3 - 5
NOVUS MED LTD
STATEMENT OF FINANCIAL POSITION
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
3
143,218
112,061
Current assets
Stocks
911,630
773,803
Debtors
1,325,359
625,868
Cash at bank and in hand
126,131
41,587
2,363,120
1,441,258
Creditors: amounts falling due within one year
(1,519,408)
(926,798)
Net current assets
843,712
514,460
Total assets less current liabilities
986,930
626,521
Creditors: amounts falling due after more than one year
(189)
(45,722)
Provisions for liabilities
4
(35,805)
(27,771)
Net assets
950,936
553,028
Capital and reserves
Called up share capital
5
100
100
Profit and loss reserves
950,836
552,928
Total equity
950,936
553,028
NOVUS MED LTD
STATEMENT OF FINANCIAL POSITION (CONTINUED)
- 2 -
For the financial year ended 30 June 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
In accordance with section 444 of the Companies Act 2006, all of the members of the company have consented to the preparation of abridged financial statements pursuant to paragraph 1A of Schedule 1 to the Small Companies and Groups (Accounts and Directors’ Report) Regulations (SI 2008/409)(b).
The directors of the company have elected not to include a copy of the income statement within the financial statements.true
The financial statements were approved by the board of directors and authorised for issue on 22 September 2025 and are signed on its behalf by:
T Martin
Director
Company registration number 10242963 (England and Wales)
NOVUS MED LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025
- 3 -
1
Accounting policies
Company information
Novus Med Ltd is a private company limited by shares incorporated in England and Wales. The registered office is Unit F15 Holly Farm Business Park, Honiley, Kenilworth, Coventry, CV8 1NP.
1.1
Basis of preparation
These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.
1.2
Turnover
Revenue comprises sales of goods or services provided to customers net of value added tax and other sales taxes, less an appropriate deduction for actual and expected returns and discounts. Revenue is recognised when performance obligations are satisfied and the control of goods or services is transferred to the buyer. Where the performance obligation is satisfied over time, revenue is recognised in accordance with its progress towards complete satisfaction of that performance obligation.
1.3
Tangible fixed assets
Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.
Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Plant and equipment
25% reducing balance basis
Fixtures and fittings
25% straight line basis
Computers
33.33% straight line basis
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.
1.4
Stocks
Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.
Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.
1.5
Taxation
The tax expense represents the sum of the tax currently payable and deferred tax.
NOVUS MED LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
1
Accounting policies
(Continued)
- 4 -
Current tax
The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.
Deferred tax
Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.
1.6
Government grants
Government grants are recognised at the fair value of the asset received or receivable.
2
Employees
The average monthly number of persons (including directors) employed by the company during the year was:
2025
2024
Number
Number
Total
12
10
3
Tangible fixed assets
Plant and equipment
Fixtures and fittings
Computers
Total
£
£
£
£
Cost
At 1 July 2024
153,030
1,736
12,957
167,723
Additions
124,480
412
3,209
128,101
Disposals
(80,566)
(80,566)
At 30 June 2025
196,944
2,148
16,166
215,258
Depreciation and impairment
At 1 July 2024
45,518
468
9,676
55,662
Depreciation charged in the year
31,644
507
1,297
33,448
Eliminated in respect of disposals
(17,070)
(17,070)
At 30 June 2025
60,092
975
10,973
72,040
Carrying amount
At 30 June 2025
136,852
1,173
5,193
143,218
At 30 June 2024
107,512
1,268
3,281
112,061
NOVUS MED LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
- 5 -
4
Provisions for liabilities
2025
2024
£
£
Deferred tax liabilities
35,805
27,771
5
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
100
100
100
100